𝔖 Bobbio Scriptorium
✦   LIBER   ✦

In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies

✍ Scribed by Ingmar Hoerr; Reinhard Obst; Hans-Georg Rammensee; Günther Jung


Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
135 KB
Volume
30
Category
Article
ISSN
0014-2980

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Human melanoma therapy in the SCID mouse
✍ Björn Cochlovius; Astrid Perschl; Gosse J. Adema; Margot Zöller 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 102 KB 👁 2 views

The adoptive transfer of tumor-specific cytotoxic T cells (CTL) offers a promising perspective in cancer immunotherapy. However, the ex vivo-generated T lymphocytes are mostly IL-2-dependent. Here we explored the possibility of circumventing the requirement for IL-2, known for severe side effects in

Generation of Melan-A/MART-1-specific CD
✍ Marina Ostankovitch; Frédérique-Anne Le Gal; Francine Connan; Dorine Chassin; Je 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 162 KB 👁 1 views

This study investigates the generation of primary melanoma cell-specific cytotoxic T lymphocytes (CTLs) in vitro. Induction of peptide-specific CTLs from unfractionated naive peripheral blood mononuclear cells from HLA-A2 healthy donors was assessed using 2 recently described 9-mer epitopes from the

Induction of prostate tumor-specific CD8
✍ Peshwa, Madhusudan V.; Shi, Jia Dong; Ruegg, Curtis; Laus, Reiner; van Schooten, 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB 👁 2 views

## BACKGROUND. Most strategies in cancer immunotherapy are aimed at the induction of a strong cellular immune response against the tumor. Particularly, CD8 + T lymphocytes have been proven in multiple animal models to be critical for the eradication of solid tumors. METHODS. We used a population o

Induction of carcinoembryonic antigen (c
✍ Smita K. Nair; Shelley Hull; Doris Coleman; Eli Gilboa; H. Kim Lyerly; Michael A 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 107 KB 👁 1 views

The application of dendritic cells (DC) to the active immunotherapy of cancer currently relies on the generation of potent DC capable of presenting tumor antigens such as carcinoembryonic antigen (CEA). It is unknown whether the T cells of patients with advanced malignancies can be reliably stimulat